The Pharma Data

JULY 25, 2021

Allergan, an AbbVie company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Production 52

Production Development Drugs Trials 52

The Pharma Data

JUNE 18, 2021

After one year, 47 percent of patients receiving risankizumab 360 mg achieved endoscopic response compared with 22 percent of patients in the induction-only control group (p<0.001). analysis plan), with 52 percent on risankizumab 360 mg achieving clinical remission versus 41 percent in the induction-only control group (p<0.01).

Trials 40

Trials Development Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 29, 2021

mg/ day achieved bettered MADRS total score at week six compared to placebo (p- value = 0.0050). mg/ day demonstrated enhancement in MADRS total score at week six over placebo but didn’t meet statistical significance (p- value = 0.0727). Cases treated with cariprazine at1.5 Cases treated with cariprazine at3.0 mg/ day or3.0

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Trials 40

The Pharma Data

FEBRUARY 22, 2021

1 In the study, 33 percent of patients receiving upadacitinib achieved clinical remission (per Adapted Mayo Score) at week 8 compared to 4 percent of patients receiving placebo (p<0.001). All primary and ranked secondary endpoints achieved p-values of <0.001 versus placebo. ” U-ACCOMPLISH Efficacy Results at Week 8 *,1.

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

JUNE 18, 2021

All differences between the overall risankizumab dose groups and placebo are statistically significant, with p-values <0.001. NORTH CHICAGO, Ill. , 1 This is the first presentation of data from these two studies, ADVANCE and MOTIVATE, following the announcement of top-line data earlier this year. Endoscopic Response c. 21/187)*. *

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

The Pharma Data

MARCH 30, 2021

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. All doses were well tolerated.

Botox 52

Botox Drugs Doctors Doctor 52

The Pharma Data

JUNE 18, 2021

1.35]; P=0.49). Avoid concomitant use of P-gp and BCRP inhibitors at initiation and during the dose titration phase. The four-year, follow-up analysis showed an OS rate of 85.4% with Ven-Obi versus 83.1% with chlorambucil in combination with obinutuzumab (Obi-Clb; HR 0.85, 95% CI [0.54-1.35];

Medicine 40

Medicine HR Trials Production 40